Hervé Tilly Selected Research

Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)

10/2022	Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.
7/2022	Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma.
1/2022	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
10/2021	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
6/2021	Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell lymphoma patients: A real-life study.
1/2021	Reproducibility of Baseline Tumour Metabolic Volume Measurements in Diffuse Large B-Cell LymphomA: Is There a Superior Method?
1/2021	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
1/2021	Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
1/2021	Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
1/2021	Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hervé Tilly Research Topics

Disease

42	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2022 - 01/2002
34	Lymphoma (Lymphomas) 03/2022 - 05/2002
28	Neoplasms (Cancer) 01/2022 - 02/2004
23	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 07/2008
21	B-Cell Lymphoma (Lymphoma, B Cell) 03/2022 - 06/2005
12	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2022 - 12/2003
9	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 12/2007
6	Infections 07/2022 - 05/2015
6	Disease Progression 01/2021 - 07/2008
6	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 01/2014
6	Neutropenia 01/2018 - 11/2005
5	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 09/2010
5	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2018 - 09/2010
4	Residual Neoplasm 01/2021 - 01/2016
3	Fatigue 01/2020 - 01/2019
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2017 - 09/2010
2	Fever (Fevers) 08/2018 - 06/2005
2	Febrile Neutropenia 01/2018 - 05/2015
2	Sarcopenia 07/2014 - 04/2014
2	Hematologic Neoplasms (Hematological Malignancy) 11/2013 - 01/2005
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2013 - 08/2011
1	Venous Thrombosis (Deep-Vein Thrombosis) 07/2022
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021
1	Leukemia 01/2021
1	Philadelphia Chromosome 01/2021
1	Leukopenia 01/2020
1	Obesity 01/2019
1	Candidiasis (Moniliasis) 08/2018

Drug/Important Bio-Agent (IBA)

50	Rituximab (Mabthera)FDA Link 03/2022 - 01/2002
17	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2002
17	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2002
16	Prednisone (Sone)FDA LinkGeneric 01/2022 - 01/2002
15	Vincristine (Oncovin)FDA LinkGeneric 01/2022 - 01/2002
9	Lenalidomide (CC 5013)FDA Link 01/2022 - 08/2017
8	obinutuzumabIBA 01/2022 - 05/2012
8	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 10/2012
6	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 01/2012
6	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021 - 09/2010
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 11/2013
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2016
5	Cell-Free Nucleic AcidsIBA 10/2020 - 07/2015
5	Monoclonal AntibodiesIBA 08/2013 - 01/2002
4	polatuzumab vedotinIBA 01/2022 - 01/2019
4	Etoposide (VP 16)FDA LinkGeneric 11/2015 - 09/2010
3	Gemcitabine FDA Link 01/2022 - 11/2013
3	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 01/2016
3	Bendamustine Hydrochloride FDA Link 01/2021 - 12/2016
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020 - 04/2015
3	Biological ProductsIBA 07/2019 - 01/2016
3	Melphalan (Alkeran)FDA LinkGeneric 11/2015 - 04/2011
3	Bleomycin (Blenoxane)FDA LinkGeneric 07/2015 - 03/2005
2	Circulating Tumor DNAIBA 01/2022 - 01/2021
2	Indicators and Reagents (Reagents)IBA 01/2021 - 11/2017
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 11/2020
2	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 11/2020
2	Pharmaceutical PreparationsIBA 01/2021 - 06/2016
2	tazemetostatIBA 11/2020 - 01/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 11/2020 - 02/2011
2	AnthracyclinesIBA 12/2017 - 01/2012
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2017 - 09/2013
2	AntigensIBA 01/2017 - 01/2002
2	Brentuximab VedotinIBA 01/2017 - 03/2016
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2016 - 06/2005
2	Histone Deacetylase InhibitorsIBA 01/2016 - 04/2015
2	Exportin 1 ProteinIBA 01/2016 - 01/2016
2	Carmustine (FIVB)FDA Link 11/2015 - 12/2014
2	Vindesine (Vindesin)IBA 12/2014 - 03/2005
2	Yttrium-90IBA 12/2014 - 04/2011
2	ibritumomab tiuxetan (Zevalin)FDA Link 12/2014 - 04/2011
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2013 - 11/2005
2	InterferonsIBA 08/2011 - 07/2008
2	Methotrexate (Mexate)FDA LinkGeneric 02/2011 - 09/2010
1	PlatinumIBA 03/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 03/2022
1	ibrutinibIBA 03/2022
1	SaltsIBA 03/2022
1	NivolumabIBA 01/2022
1	Arginine (L-Arginine)FDA Link 04/2021
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 04/2021
1	FluorineIBA 04/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Histones (Histone)IBA 01/2020
1	TransferasesIBA 01/2020
1	pinatuzumab vedotinIBA 05/2019
1	Busulfan (Busulfex)FDA Link 08/2018

Therapy/Procedure

35	Therapeutics 10/2022 - 05/2002
34	Drug Therapy (Chemotherapy) 01/2022 - 01/2002
15	Stem Cell Transplantation 03/2022 - 05/2002
4	Induction Chemotherapy 11/2020 - 12/2003
4	Transplantation 11/2020 - 05/2007
3	Ligation 01/2020 - 04/2015
3	Salvage Therapy 01/2016 - 07/2008
3	BEAM regimen 11/2015 - 04/2011
2	Autologous Transplantation 01/2021 - 08/2011
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 01/2017
2	VAP-cyclo protocol 05/2013 - 01/2002
2	Radiotherapy 03/2007 - 03/2005
2	Chemoradiotherapy 03/2007 - 03/2005
1	Vascular Access Devices (Arterial Line) 07/2022
1	Catheters 07/2022